Your browser doesn't support javascript.
loading
Triggering interferon signaling in T cells with avadomide sensitizes CLL to anti-PD-L1/PD-1 immunotherapy.
Ioannou, Nikolaos; Hagner, Patrick R; Stokes, Matt; Gandhi, Anita K; Apollonio, Benedetta; Fanous, Mariam; Papazoglou, Despoina; Sutton, Lesley-Ann; Rosenquist, Richard; Amini, Rose-Marie; Chiu, Hsiling; Lopez-Girona, Antonia; Janardhanan, Preethi; Awan, Farrukh T; Jones, Jeffrey; Kay, Neil E; Shanafelt, Tait D; Tallman, Martin S; Stamatopoulos, Kostas; Patten, Piers E M; Vardi, Anna; Ramsay, Alan G.
Afiliación
  • Ioannou N; School of Cancer and Pharmaceutical Sciences, Faculty of Life Sciences & Medicine, King's College London, London, United Kingdom.
  • Hagner PR; Bristol-Myers Squibb, Summit, NJ.
  • Stokes M; Bristol-Myers Squibb, Summit, NJ.
  • Gandhi AK; Bristol-Myers Squibb, Summit, NJ.
  • Apollonio B; School of Cancer and Pharmaceutical Sciences, Faculty of Life Sciences & Medicine, King's College London, London, United Kingdom.
  • Fanous M; School of Cancer and Pharmaceutical Sciences, Faculty of Life Sciences & Medicine, King's College London, London, United Kingdom.
  • Papazoglou D; School of Cancer and Pharmaceutical Sciences, Faculty of Life Sciences & Medicine, King's College London, London, United Kingdom.
  • Sutton LA; Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
  • Rosenquist R; Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
  • Amini RM; Clinical Genetics, Karolinska University Hospital Solna, Stockholm, Sweden.
  • Chiu H; Department of Immunology, Genetics and Pathology, Uppsala University and University Hospital, Uppsala, Sweden.
  • Lopez-Girona A; Bristol-Myers Squibb, Summit, NJ.
  • Janardhanan P; Bristol-Myers Squibb, San Diego, CA.
  • Awan FT; Bristol-Myers Squibb, San Diego, CA.
  • Jones J; Division of Hematology, The Ohio State University Cancer Center, Columbus, OH.
  • Kay NE; Bristol-Myers Squibb, Summit, NJ.
  • Shanafelt TD; Division of Hematology, Mayo Clinic, Rochester, MN.
  • Tallman MS; Stanford University, School of Medicine, Stanford, CA.
  • Stamatopoulos K; Memorial Sloan-Kettering Cancer Center, New York, NY.
  • Patten PEM; Institute of Applied Biosciences, Centre for Research and Technology Hellas, Thessaloniki, Greece.
  • Vardi A; School of Cancer and Pharmaceutical Sciences, Faculty of Life Sciences & Medicine, King's College London, London, United Kingdom.
  • Ramsay AG; Department of Haematology, King's College Hospital NHS Foundation Trust, London, United Kingdom; and.
Blood ; 137(2): 216-231, 2021 01 14.
Article en En | MEDLINE | ID: mdl-33024998
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Piperidonas / Activación de Linfocitos / Linfocitos T / Leucemia Linfocítica Crónica de Células B / Quinazolinonas / Inhibidores de Puntos de Control Inmunológico Límite: Animals / Humans Idioma: En Revista: Blood Año: 2021 Tipo del documento: Article País de afiliación: Reino Unido Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Piperidonas / Activación de Linfocitos / Linfocitos T / Leucemia Linfocítica Crónica de Células B / Quinazolinonas / Inhibidores de Puntos de Control Inmunológico Límite: Animals / Humans Idioma: En Revista: Blood Año: 2021 Tipo del documento: Article País de afiliación: Reino Unido Pais de publicación: Estados Unidos